Biogen has signed up with a GlaxoSmithKline-founded effort to better understand the underlying biology of disease, hoping to map out better targets for future therapies by collaborating on early-stage research.
Bavarian Nordic has signed up to work with Evaxion Biotech on the development of a vaccine against the antibiotic-resistant bacterium MRSA. The project is underpinned by Eden Technology, an in silico vaccine discovery platform that combines data, algorithms and deep learning to unearth antigens.
A little more than a week after Cambridge, MA-based Akashi Therapeutics suspended its study of a new drug for Duchenne muscular dystrophy after a patient was sent to the hospital, the biotech reports that the trial subject has died.
Johnson & Johnson has partnered with Cue to develop a portable, inexpensive and internet-enabled HIV viral load test that would enable physicians in poor countries to more easily determine if a particular drug regimen is effective or not.
Paris-based Cellnovo Group has partnered with TypeZero Technologies to be part of a previously announced clinical trial of an artificial pancreas that's being backed by a $12.8 million grant from the U.S. National Institutes of Health. Cellnovo's connected insulin patch pump will be used in conjunction with TypeZero's inControl AP software and a Dexcom continuous glucose monitor to form the whole of the artificial pancreas system being tested.
Last June, the National Academies' Institute of Medicine hosted a two-day workshop in Washington, DC, aimed at promoting clinical research in dogs that can be translated to finding new cures for people. Now the IOM is sharing insights that came from the more than 20 veterinarians and scientists who attended the event.
Biopharmas may be able to command hundreds of dollars a month for prescription medications, but it can be tough to get payers to cough up even a few bucks for an app that may offer comparable levels of benefit. So, one startup, Pear Therapeutics, has adopted the language of biopharma and it is looking to work tightly in tandem with drug companies with medication adherence apps.
The Michael J. Fox Foundation awarded a grant to Evotec to support the company's work in Parkinson's disease, bankrolling a project meant to clear the way for new therapies.
Spero Therapeutics raises $30M to support its drug delivery platform targeting Gram-negative bacteria
Cambridge, MA's Spero Therapeutics has raised $30 million in Series B financing to develop its so-called Potentiator Platform to improve existing antibiotics by enabling them to pass through the cell membrane of Gram-negative bacteria.
Cats with a debilitating tooth ailment called feline chronic gingivostomatitis sometimes experience pain even after getting their teeth removed or taking multiple doses of antibiotics or steroids. But a new treatment that draws on the cats' own stem cells could prove game-changing in helping animals that are suffering from the disease. The findings could also apply to humans with oral diseases.